PL1899334T3 - Związki naftyrydynowe - Google Patents

Związki naftyrydynowe

Info

Publication number
PL1899334T3
PL1899334T3 PL06773519T PL06773519T PL1899334T3 PL 1899334 T3 PL1899334 T3 PL 1899334T3 PL 06773519 T PL06773519 T PL 06773519T PL 06773519 T PL06773519 T PL 06773519T PL 1899334 T3 PL1899334 T3 PL 1899334T3
Authority
PL
Poland
Prior art keywords
sub
naphthyridine compounds
histamine
receptor
serotonin
Prior art date
Application number
PL06773519T
Other languages
English (en)
Inventor
Michael A Letavic
John M Keith
Nicholas I Carruthers
Chandravadan R Shah
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of PL1899334T3 publication Critical patent/PL1899334T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Otolaryngology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL06773519T 2005-06-17 2006-06-16 Związki naftyrydynowe PL1899334T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US69200305P 2005-06-17 2005-06-17
EP06773519A EP1899334B1 (en) 2005-06-17 2006-06-16 Naphthyridine compounds
PCT/US2006/023788 WO2006138714A2 (en) 2005-06-17 2006-06-16 Naphthyridine compounds

Publications (1)

Publication Number Publication Date
PL1899334T3 true PL1899334T3 (pl) 2009-04-30

Family

ID=37263777

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06773519T PL1899334T3 (pl) 2005-06-17 2006-06-16 Związki naftyrydynowe

Country Status (14)

Country Link
US (1) US7417054B2 (pl)
EP (1) EP1899334B1 (pl)
JP (1) JP2008543880A (pl)
CN (1) CN101243083A (pl)
AT (1) ATE409188T1 (pl)
AU (1) AU2006261162A1 (pl)
CA (1) CA2612409A1 (pl)
DE (1) DE602006002894D1 (pl)
DK (1) DK1899334T3 (pl)
ES (1) ES2314933T3 (pl)
PL (1) PL1899334T3 (pl)
PT (1) PT1899334E (pl)
SI (1) SI1899334T1 (pl)
WO (1) WO2006138714A2 (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030078347A1 (en) * 2001-08-28 2003-04-24 General Electric Company Triazine compounds, polymers comprising triazine structural units, and method
CN103788089A (zh) * 2003-09-17 2014-05-14 詹森药业有限公司 作为血清素受体调节剂的稠合杂环化合物
AU2006259257A1 (en) * 2005-06-17 2006-12-28 Janssen Pharmaceutica N.V. Hexahydro-pyrrolo-isoquinoline compounds for the treatment of CNS disorders
US7598255B2 (en) * 2005-08-04 2009-10-06 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
EP2049473A2 (en) * 2006-06-29 2009-04-22 Janssen Pharmaceutica N.V. Substituted benzyl amine compounds
CN101511775A (zh) * 2006-06-29 2009-08-19 詹森药业有限公司 丁基和丁炔基苄基胺化合物
EP2046747A1 (en) * 2006-06-29 2009-04-15 Janssen Pharmaceutica N.V. Substituted aminomethyl benzamide compounds
FR2903904A1 (fr) * 2006-07-21 2008-01-25 Bioprojet Soc Civ Ile Association de modafinil et d'un antagoniste ou agoniste inverse du recepteur h3
TW200823204A (en) * 2006-10-17 2008-06-01 Arena Pharm Inc Biphenyl sulfonyl and phenyl-heteroaryl sulfonyl modulators of the histamine H3-receptor useful for the treatment of disorders related thereto
WO2008064036A1 (en) * 2006-11-16 2008-05-29 Janssen Pharmaceutica N.V. Substituted phenyl propyl amines as histamine h3 receptor and serotonin transporter modulators
WO2008109336A1 (en) 2007-03-01 2008-09-12 Janssen Pharmaceutica N.V. Tetrahydroisoquinoline compounds as modulators of the histamine h3 receptor
WO2008144305A1 (en) 2007-05-18 2008-11-27 Janssen Pharmaceutica N.V. Diaryl-substituted tetrahydroisoquinolines as histamine h3 receptor and serotonin transporter modulators
JP2011518127A (ja) * 2008-03-31 2011-06-23 エヴォテック・アクチエンゲゼルシャフト ヒスタミンh3受容体アンタゴニストとしてのテトラヒドロナフチリジンおよびそれらのアザ誘導体
JP5364327B2 (ja) * 2008-09-26 2013-12-11 富士フイルム株式会社 ハロピラジンカルボキサミド化合物の製造方法
WO2016089800A1 (en) * 2014-12-02 2016-06-09 Boehringer Ingelheim International Gmbh Aldosterone synthase inhibitors
CN113024456B (zh) * 2021-02-23 2022-05-13 江苏先导药业有限公司 一种2-氯烟酸的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH527194A (de) * 1970-01-06 1972-08-31 Hoffmann La Roche Verfahren zur Herstellung von Isochinolin-Derivaten
GB1504424A (en) 1975-08-09 1978-03-22 Beecham Group Ltd Isoquinoline-derived aminoethers
GB1558043A (en) * 1976-02-03 1979-12-19 Onoda Cement Co Ltd Metal squeeze out tube and method and apparatus for forming a powder layer on its surface
DK0831829T3 (da) * 1995-06-07 2003-12-15 Pfizer Heterocykliske, ringkondenserede pyrimidinderivater
EP0978512A1 (en) * 1998-07-29 2000-02-09 Societe Civile Bioprojet Non-imidazole aryloxy (or arylthio) alkylamines as histamine H3-receptor antagonists and their therapeutic applications
KR20080065707A (ko) 1999-11-03 2008-07-14 에이엠알 테크놀로지, 인크. 4-페닐-치환 테트라히드로이소퀴놀린, 및 노르에피네프린과도파민과 세로토닌의 재흡수를 차단하기 위한 이의 용도
EP1113007A1 (en) 1999-12-24 2001-07-04 Pfizer Inc. Tetrahydroisoquinoline compounds as estrogen agonists/antagonists
EP1595881A1 (en) * 2004-05-12 2005-11-16 Pfizer Limited Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands
WO2006066197A1 (en) * 2004-12-17 2006-06-22 Janssen Pharmaceutica, N.V. Tetrahydroisoquinoline compounds for treatment of cns disorders

Also Published As

Publication number Publication date
WO2006138714A2 (en) 2006-12-28
SI1899334T1 (sl) 2009-04-30
JP2008543880A (ja) 2008-12-04
WO2006138714A3 (en) 2007-03-15
DE602006002894D1 (de) 2008-11-06
ATE409188T1 (de) 2008-10-15
CA2612409A1 (en) 2006-12-28
PT1899334E (pt) 2008-11-06
DK1899334T3 (da) 2008-11-24
EP1899334A2 (en) 2008-03-19
US7417054B2 (en) 2008-08-26
EP1899334B1 (en) 2008-09-24
CN101243083A (zh) 2008-08-13
ES2314933T3 (es) 2009-03-16
AU2006261162A1 (en) 2006-12-28
US20060287292A1 (en) 2006-12-21

Similar Documents

Publication Publication Date Title
SG146683A1 (en) Fused heterocyclic compounds as serotonin receptor modulators
SI1899334T1 (sl) Naftiridinske spojine
WO2008002820A3 (en) Substituted benzyl amine compounds
IL213679A0 (en) Pyrimidine compounds as serotonin receptor modulators
ATE407927T1 (de) 3-phenyl-pyrazol-derivate als modulatoren des zur behandlung damit zusammenhängender störungen nützlichen 5-ht-2a-serotonin-rezeptors
ATE496892T1 (de) Tetrahydroisochinolinverbindungen zur behandlung von zns-erkrankungen
CL2008001122A1 (es) Compuestos derivados de imidazo[1,2,3-ij]-1,8-naftiridin-4,9-diona; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de infecciones bacterianas.
MX2009004516A (es) Metodos y terapias de combinacion para tratar enfermedad de alzheimer.
UA89734C2 (en) ANTAGONISTS of muscarinic acetylcholine receptors
CL2009000161A1 (es) Compuestos derivados de 2,3,4,5-tetrahidro-1h-pirido[4,3-b]indol; composicion farmaceutica que los comprende; uso en el tratamiento de trastornos neurodegenerativos, cognitivos o psicoticos, enfermedad de alzheimer, entre otros; y un kit que contiene a los compuestos.
AT9566U3 (de) Kopierfräseinrichtung zur herstellung von zahntechnischen werkstücken
CL2009000697A1 (es) Compuestos derivados de 2-heteroaril-6-fenil-imidazol [1,2-a]piridinas sustituidas; moduladores de receptores not; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de cancer, inflamacion, enfermedades neurodegenerativas, psiquiatricas, epilepsia, entre otras.
IL171974A0 (en) Tetrahydrocarbazole derivatives and their pharmaceutical use
AU2003290059A8 (en) Use of cd137 antagonists for the treatment of tumors
DE602004014772D1 (de) Pyrrol-2,5-dithionderivate als modulatoren des liver-x-rezeptors
TW200510398A (en) Novel compounds
MXPA05013478A (es) Combinaciones terapeuticas.
NO20055563L (no) Midler for behandlingen av lavere abdominale lidelser
IL162154A0 (en) Prostagandin composition for the treatment of erectile dysfunction
WO2006116311A3 (en) Opioid receptor agonist compounds and their use in treatment of pain
EG24959A (en) Indoles useful in the treatment of androgenreceptor related diseases.
CY1110846T1 (el) Διαμορφωτες υποδοχεων της προγεστερονης του τυπου πυριδοοξαζεπινης
TW200744607A (en) Pyrimidine compounds as serotonin receptor modulators
GB0515025D0 (en) Organic compounds
GB0508988D0 (en) Organic compounds